Vericel (VCEL) Net Income towards Common Stockholders (2010 - 2026)

Vericel's (VCEL) quarterly Net Income towards Common Stockholders came in at -$6.4 million in Q1 2026, up 43.54% year-on-year from -$4.4 million in Q1 2025, and down 126.4% quarter-over-quarter from $24.1 million in Q4 2025.

Vericel (VCEL) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Vericel has disclosed Net Income towards Common Stockholders across 17 years of filings, most recently posting -$6.4 million for Q1 2026.

  • Net Income towards Common Stockholders for Q1 2026 came in at -$6.4 million, up 43.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.3 million (up 658.7% YoY), and the FY2025 annual result was $16.5 million, up 59.41% from the prior year.
  • Net Income towards Common Stockholders came in at -$6.4 million for Q1 2026 at Vericel, down from $24.1 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $24.1 million in Q4 2025 to a low of -$11.3 million in Q1 2025.
  • The 5-year median for Net Income towards Common Stockholders is -$3.9 million (2024), against an average of $91235.3.
  • Peak annual rise in Net Income towards Common Stockholders reached 666.04% in 2025, while the deepest fall reached 192.81% in 2025.
  • Vericel's Net Income towards Common Stockholders stood at $5.9 million in 2022, then soared by 119.4% to $13.0 million in 2023, then jumped by 52.44% to $19.8 million in 2024, then rose by 21.87% to $24.1 million in 2025, then tumbled by 126.4% to -$6.4 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$6.4 million (Q1 2026), $24.1 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -13.56 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 2.50 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.63 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 Vericel 2.04 Bn 1.90 Bn 49.27 Mn -6.37 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -6.37 Mn
Dec 31, 2025 24.14 Mn
Sep 30, 2025 5.10 Mn
Jun 30, 2025 -529,000.00
Mar 31, 2025 -11.29 Mn
Dec 31, 2024 19.81 Mn
Sep 30, 2024 -901,000.00
Jun 30, 2024 -4.67 Mn
Mar 31, 2024 -3.86 Mn
Dec 31, 2023 12.99 Mn
Sep 30, 2023 -3.66 Mn
Jun 30, 2023 -5.02 Mn
Mar 31, 2023 -7.48 Mn
Dec 31, 2022 5.92 Mn
Sep 30, 2022 -6.58 Mn
Jun 30, 2022 -8.96 Mn
Mar 31, 2022 -7.09 Mn
Dec 31, 2021 4.54 Mn
Sep 30, 2021 -4.93 Mn
Jun 30, 2021 -3.79 Mn